Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | KRAS | P01116 | 7/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | HMOX2 | P30519 | 1/20 | 0.46 |
| ▸ | CRYZ | Q08257 | 1/20 | 0.46 |
| ▸ | VAT1 | Q99536 | 1/20 | 0.46 |
| ▸ | RTN4 | Q9NQC3 | 1/20 | 0.46 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GALR2 | O43603 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29611722 | 1.00 | KIT (0.50) | KITCNR1CNR2KRASEGFR | |
| SCHEMBL21415570 | 0.90 | KIT (0.52) | KITCNR1CNR2KRASEGFR | |
| SCHEMBL16647196 | 0.90 | KIT (0.52) | KITCNR1CNR2KRASEGFR | |
| SCHEMBL21415487 | 0.89 | KIT (0.51) | KITCNR1CNR2KRASEGFR | |
| SCHEMBL26967337 | 0.88 | KIT (0.50) | KITCNR1CNR2KRASEGFR | |
| SCHEMBL24918229 | 0.87 | KIT (0.49) | KITCNR1CNR2KRASEGFR | |
| SCHEMBL16637088 | 0.87 | KIT (0.49) | KITCNR1CNR2MAP4K4KCNH2 | |
| SCHEMBL16637001 | 0.86 | KCNH2 (0.42) | KITCNR1CNR2MAP4K4GRIA1 | |
| SCHEMBL29409403 | 0.86 | KCNH2 (0.42) | KITCNR1CNR2MAP4K4GRIA1 | |
| SCHEMBL24161673 | 0.86 | GBA1 (0.43) | KITCNR1CNR2MAP4K4GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | BIOTHERYX, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-RE50490-E1 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2025-07-15 | — | — | US | disclosed |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | ARAXES PHARMA LLC (US) | 2025-02-25 | — | — | US | disclosed |
| US-20250059163-A1 | FUSED RING COMPOUNDS | GENENTECH INC (US) | 2025-02-20 | — | — | US | disclosed |
| EP-4483881-A2 | FUSED RING COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2024-10-24 | — | — | US | disclosed |
| EP-3735299-B1 | FUSED RING COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2024-10-02 | — | — | EP | disclosed |
| US-12084429-B2 | Fused ring compounds | GENENTECH, INC. (US) | 2024-09-10 | — | — | US | disclosed |
| US-20240246954-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KRAS | THERAS, INC. | 2024-07-25 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2016-10-13 | — | — | US | disclosed |
| EP-3055290-A1 | INHIBITORS OF KRAS G12C | Araxes Pharma LLC (US) | 2016-08-17 | — | — | EP | disclosed |
| WO-2016049568-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF RAS | ARAXES PHARMA LLC (US) | 2016-03-31 | — | — | WO | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC | 2015-08-27 | — | — | US | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| WO-2015054572-A1 | INHIBITORS OF KRAS G12C | ARAXES PHARMA LLC (US) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240246954-A1 | COMPOSITIONS AND METHODS FOR INHIBITING KRAS | KRAS, NRAS, HRAS | KIT 1978/4885CNR1 3434/4885CNR2 3612/4885 |
| US-12630547-B2 | RAS protein degraders, pharmaceutical compositions thereof, and their therapeutic applications | KRAS, RSU1, NRAS | KIT 3332/4885CNR1 1146/4885CNR2 2162/4885 |
| US-12234244-B2 | Substituted piperazines as inhibitors of KRAS G12C | KRAS, NRAS, HRAS | KIT 4086/4885CNR1 3613/4885CNR2 4274/4885 |
| US-12084429-B2 | Fused ring compounds | KRAS, NRAS, HRAS | KIT 1555/4885CNR1 3302/4885CNR2 3552/4885 |
| US-20250059163-A1 | FUSED RING COMPOUNDS | KRAS, NRAS, HRAS | KIT 1555/4885CNR1 3302/4885CNR2 3552/4885 |
| US-20160297774-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | KIT 2021/4885CNR1 1231/4885CNR2 2011/4885 |
| US-20240352028-A1 | SUBSTITUTED QUINAZOLINES AS INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KIT 3330/4885CNR1 2883/4885CNR2 3665/4885 |
| US-20150239900-A1 | INHIBITORS OF KRAS G12C | KRAS, NRAS, HRAS | KIT 4380/4885CNR1 3222/4885CNR2 4236/4885 |
| US-12552783-B2 | Modulators of proteolysis and associated methods of use | CRBN, ADRM1, MDM2 | KIT 3038/4885CNR1 3202/4885CNR2 3943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.